by Greg Kuehn | Mar 20, 2020 | Research News
Research will examine prevalent gut microbial markers present in colorectal cancer CARLSBAD, Calif., June 2, 2020 /PRNewswire/ — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., announced today a research...
by Greg Kuehn | Dec 17, 2019 | Research News
CARLSBAD, Calif., Dec. 17, 2019 /PRNewswire/ — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of OraSure Technologies, Inc., announced today a collaboration to develop a new test called LifeKit®...
by Greg Kuehn | Sep 5, 2019 | Press Releases
CARLSBAD, Calif., Sept. 4, 2019 /PRNewswire/ — Prescient Metabiomics, a privately held company and a subsidiary of Prescient Medicine Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted the company’s submission...
by Greg Kuehn | Sep 18, 2018 | Press Releases
Innovative new microbiome GI health solutions battle colon cancer and gastrointestinal disease Chicago, Sept. 18, 2018 – Prescient Medicine Holdings, LLC and Metabiomics Corp., have announced a joint venture to develop an innovative microbiome diagnostics platform for...
by Greg Kuehn | Apr 15, 2018 | Research News
Patrick M. Gillevet, Ezzat Dadkhah, Masoumeh Sikaroodi, Swati Dalmet, Louis Y. Korman, Robert Hardi, Jeffrey H. Baybick, David K. Hanzel, Greg Kuehn, Thomas Kuehn Background: Alterations in the colonic microbiota are likely to play a role in colonic...
